Literature DB >> 15572815

Oral itraconazole in treatment of candidemia in a pediatric intensive care unit.

Sunit C Singhi1, Thimmapuram C S Reddy, Arunaloke Chakrabarti.   

Abstract

OBJECTIVE: To examine efficacy of itraconazole in the treatment of candidemia in critically ill children.
METHODS: We studied retrospectively cases of candidemia seen consecutively in our Pediatric Intensive Care Unit (PICU) over three and half years. Candida isolates from those patients included. Candida albicans--19, C. tropicalis--31, C. guillermondii--9, C.krusei--4 and C. glabrata--1.
RESULTS: Of the 64 patients, 48 (75%) had symptoms suggestive of septicemia and 16 had no symptoms suggestive of septicemia. No antifungal therapy was given to asymptomatic patients; they recovered from candidemia without development of any sequelae. Of the 48 symptomatic patients 11 died before results of fungal culture became available and antifungal therapy could be started. Thirty seven patients were treated with itraconazole (10 mg/kg/day orally or through gastric tube). Seven (18.9 %) of 37 patients died, 3 within first week of antifungal therapy. Thirty (81%) patients recovered; microbiological cure was noted on average by day 14 (range 4-30 days). The mean +/- SD duration of therapy in patients who responded was 24 +/-7 days (range 21-42 days). None had any major side effect.
CONCLUSION: We conclude that oral itraconazole may be effective in treatment of candidemia in children in a PICU where non-C. albicans candida species constituted majority (70%) of all Candida isolates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15572815     DOI: 10.1007/bf02828109

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  24 in total

Review 1.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

2.  Pediatric nosocomial fungal infections.

Authors:  N C Chiu; Y F Chung; F Y Huang
Journal:  Southeast Asian J Trop Med Public Health       Date:  1997-03       Impact factor: 0.267

3.  Mortality associated with systemic candidiasis in children.

Authors:  A Pacheco-Ríos; C Avila-Figueroa; D Nobigrot-Kleinman; J I Santos
Journal:  Arch Med Res       Date:  1997       Impact factor: 2.235

Review 4.  Azole antifungal drugs: old and new.

Authors:  W E Dismukes
Journal:  Ann Intern Med       Date:  1988-08-01       Impact factor: 25.391

5.  Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results.

Authors:  B Dupont; E Drouhet
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

6.  A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients.

Authors:  M Nucci; I Biasoli; T Akiti; F Silveira; C Solza; G Barreiros; N Spector; A Derossi; W Pulcheri
Journal:  Clin Infect Dis       Date:  2000-02       Impact factor: 9.079

7.  Candidemia in children with central venous catheters: role of catheter removal and amphotericin B therapy.

Authors:  V M Dato; A S Dajani
Journal:  Pediatr Infect Dis J       Date:  1990-05       Impact factor: 2.129

Review 8.  Candidemia in a pediatric population.

Authors:  J K Stamos; A H Rowley
Journal:  Clin Infect Dis       Date:  1995-03       Impact factor: 9.079

Review 9.  Oral azole drugs as systemic antifungal therapy.

Authors:  J A Como; W E Dismukes
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

Review 10.  Itraconazole in the treatment of superficial cutaneous and mucosal Candida infections.

Authors:  J Q Del Rosso; S Zellis; A K Gupta
Journal:  J Am Osteopath Assoc       Date:  1998-09
View more
  4 in total

1.  Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants.

Authors:  Arne Simon; Mette Besuden; Sandra Vezmar; Carola Hasan; Dagmar Lampe; Sigrid Kreutzberg; Axel Glasmacher; Udo Bode; Gudrun Fleischhack
Journal:  Support Care Cancer       Date:  2006-08-30       Impact factor: 3.603

2.  Risk factors for candidemia in pediatric intensive care unit patients.

Authors:  Hasan Ağın; Ilker Devrim; Rana Işgüder; Utku Karaarslan; Esra Kanık; Ilker Günay; Miray Kışla; Sultan Aydın; Gamze Gülfidan
Journal:  Indian J Pediatr       Date:  2014-03-14       Impact factor: 1.967

Review 3.  Invasive candidiasis in pediatric intensive care units.

Authors:  Sunit Singhi; Akash Deep
Journal:  Indian J Pediatr       Date:  2009-11-12       Impact factor: 1.967

Review 4.  Efficacy and safety of itraconazole use in infants.

Authors:  Shuang Chen; Kai-Yi Sun; Xiao-Wei Feng; Xin Ran; Jebina Lama; Yu-Ping Ran
Journal:  World J Pediatr       Date:  2016-06-10       Impact factor: 9.186

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.